ALX Oncology Overview

  • Founded
  • 2015

Founded
  • Status
  • Public

  • Employees
  • 55

Employees
  • Stock Symbol
  • ALXO

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $9.30

  • (As of Tuesday Closing)

ALX Oncology General Information

Description

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Contact Information

Formerly Known As
Alexo Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 866 Malcolm Road
  • Suite 100
  • Burlingame, CA 94010
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ALX Oncology Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.30 $9.28 $5.82 - $20.40 $378M 40.8M 174K -$2.98

ALX Oncology Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 77,658 485,889 2,944,944
Revenue 0 0 1,182 4,796
EBITDA (123,349) (83,420) (44,486) (18,759)
Net Income (121,211) (83,463) (45,740) (19,243)
Total Assets 317,689 380,183 436,054 10,676
Total Debt 6,600 742 0 5,421
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ALX Oncology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ALX Oncology‘s full profile, request access.

Request a free trial

ALX Oncology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by develo
Drug Discovery
Burlingame, CA
55 As of 2022
00000
00000000 00000

000000

oris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehend
0000000000000
Vancouver, Canada
000 As of 0000
00000
0000 0000-00-00
000000000000

00000

a aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nis
0000 000000000
Wadenswil, Switzerland
00 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ALX Oncology Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Zymeworks Formerly VC-backed Vancouver, Canada 000 00000 000000000000
00000 0000 0000000 Venture Capital-Backed Wadenswil, Switzerland 00 00000 00000000000 00000
You’re viewing 2 of 2 competitors. Get the full list »

ALX Oncology Patents

ALX Oncology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220363779-A1 Combination therapies for treating cancer Pending 13-May-2021 000000000
US-20220196651-A1 Multimers for reducing the interference of drugs that bind cd47 in serological assays Pending 06-Dec-2020 000000000000
US-20220401516-A1 Combination therapies comprising a hypomethylation agent for treating cancer Pending 01-Jun-2020 00000000000
CA-3178157-A1 Combination therapies comprising a hypomethylation agent for treating cancer Pending 01-Jun-2020
AU-2021283083-A1 Combination therapies comprising a hypomethylation agent for treating cancer Pending 01-Jun-2020 A61K38/1703
To view ALX Oncology’s complete patent history, request access »

ALX Oncology Executive Team (12)

Name Title Board Seat Contact Info
Jaume Pons Ph.D Chief Executive Officer & Founder
Peter Garcia Chief Financial Officer, Finance
Shelly Pinto Chief Accounting Officer, Accounting & Vice President
Jeanne Jew Chief Business Officer
Hank Stern Vice President, Chemistry, Manufacturing & Controls
You’re viewing 5 of 12 executive team members. Get the full list »

ALX Oncology Board Members (11)

Name Representing Role Since
Caroline Gaynor Lightstone Ventures Board Member 000 0000
Corey Goodman Ph.D ALX Oncology Chairman & Board Member 000 0000
Itziar Canamasas ALX Oncology Board Member 000 0000
Jack Nielsen Vivo Capital Board Member 000 0000
Jason Lettmann Lightstone Ventures Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

ALX Oncology Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ALX Oncology Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 04-Oct-2021 0000000000 00.00 Biotechnology
To view ALX Oncology’s complete acquisitions history, request access »

ALX Oncology ESG

Risk Overview

Risk Rating

Updated December, 06, 2022

30.92 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,613

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,004

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 462

Rank

00.00

Percentile

To view ALX Oncology’s complete esg history, request access »